There is a synthetic lethal relationship between SMARCA4 and the PTEN tumor suppressor in prostate cancer, rendering PTEN-deficient cells sensitive to SMARCA4 inhibition [111]. This evidence concerns the gene SMARCA4 and prostate carcinoma.